The potential benefits of aldosterone antagonism in type 2 diabetes mellitus

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 3, Issue 3, 2002, Pages 150-155

  Davies, Justine ^a   Struthers, Allan ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Aldosterone; Diabetes; Spironolactone

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; RAMIPRIL; SPIRONOLACTONE;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HEART FAILURE; HEART INFARCTION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYMPATHETIC TONE; VASCULAR ENDOTHELIUM;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; DIABETES MELLITUS, TYPE 2; ENDOTHELIUM, VASCULAR; HUMANS; MAGNESIUM; PARASYMPATHETIC NERVOUS SYSTEM; POTASSIUM; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM;

EID: 0036756566     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/14703203020030030301     Document Type: Article

References (67)

1. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
2. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000;355:253-9.
3. Fontbonne A, Charles MA, Thibult N et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991;34:356-61.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
5. MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999;82:57-61.
6. Farquharson CA, Struthers AD. Gradual reactivation over time of vascular tissue angiotensin I to angiotensin II conversion during chronic lisinopril therapy in chronic heart failure. J Am Coll Cardiol 2002;39:767-75.
7. Cohn JN, Tognoni G. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
8. Struthers AD. Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure? Br J Clin Pharmacol 1999;47:479-82.
9. Golestaneh N, Klein C, Valamanesh F, Suarez G, Agarwal MK, Mirshahi M. Mineralocorticoid receptor-mediated signaling regulates the ion gated sodium channel in vascular endothelial cells and requires an intact cytoskeleton. Biochem Biophys Res Commun 2001;280:1300-06.
10. Watzka M, Beyenburg S, Blumcke I, Elger CE, Bidlingmaier F, Stoffel-Wagner B. Expression of mineralocorticoid and glucocorticoid receptor mRNA in the human hippocampus. Neurosci Lett 2000;290:121-4.
11. Wickert L, Selbig J, Watzka M et al. Differential mRNA expression of the two mineralocorticoid receptor splice variants within the human brain: structure analysis of their different DNA binding domains. J Neuroendocrinol 2000;12:867-73.
12. Dzau VJ. Local expression and pathophysiological role of renin-angiotensin in the blood vessels and heart. Basic Res Cardiol 1993;88(suppl 1):1-14.
13. Mizuno Y, Yoshimura M, Yasue H et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-7.
14. Okamura T, Aimi Y, Kimura H, Murakami K, Toda N. Existence of renin in the endothelium of human artery. J Hypertens 1992;10:49-53.
15. Engeli S, Gorzelniak K, Kreutz R, Runkel N, Distler A, Sharma AM. Co-expression of renin-angiotensin system genes in human adipose tissue. J Hypertens 1999;17:555-60.
16. Price DA, De'Oliveira JM, Fisher ND, Williams GH, Hollenberg NK. The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. Am J Hypertens 1999;12:348-55.
17. Chan JC, Cheung CK, Cockram CS et al. Atrial natriuretic peptide and renin-angiotensin-aldosterone system in non-insulin-dependent diabetes mellitus. J Hum Hypertens 1994; 8:451-6.
18. Ferriss JB, Sullivan PA, Gonggrijp H, Cole M, O'Sullivan DJ. Plasma angiotensin II and aldosterone in unselected diabetic patients. Clin Endocrinol 1982;17:261-9.
19. de Chatel R, Weidmann P, Flammer J et al. Sodium, renin, aldosterone, catecholamines and blood pressure in diabetes. Kidney Int 1977; 12:412-21.
20. McKnight JA, Sheridan B, Roberts G, Atkinson AB. Basal and stimulated plasma atrial natriuretic factor in type 2 diabetes. Diabetes Res 1991;18:143-8.
21. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992;19:403-18.
22. Swislocki AL, Siegel D. Renal effects of angiotensin-converting enzyme inhibitors that result in cost savings and improved patient outcomes. Am J Manag Care 2001;7:283-95.
23. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
24. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
25. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004-10.
26. Petrie JR, Morris AD, Ueda S et al. Trandolapril does not improve insulin sensitivity in patients with hypertension and type 2 diabetes: a double-blind, placebo-controlled crossover trial. J Clin Endocrinol Metab 2000;85:1882-9.
27. Seghieri G, Yin W, Boni C et al. Effect of chronic ACE inhibition on glucose tolerance and insulin sensitivity in hypertensive type 2 diabetic patients. Diabet Med 1992;9:732-8.
28. Vuorinen-Markkola H, Yki-Jarvinen H. Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Metabolism 1995;44:85-9.
29. Yin W, Seghieri G, Boni C et al. Effect of chronic ACE inhibition on glucose tolerance and insulin sensitivity in hypertensive type 2 diabetic patients. Chin Med Sci J 1994;9:29-33.
30. Estacio RO, Jeffers BW, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care 2000;23(suppl 2):B54-B64.
31. Tatti P, Pahor M, Byington RP et al. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
32. Fontbonne A, Charles MA, Thibult N et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia 1991;34:356-61.
33. Cheetham C, O'Driscoll G, Stanton K, Taylor R, Green D. Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. Clin Sci 2001;100:13-17.
34. O'Driscoll G, Green D, Maiorana A, Stanton K, Colreavy F, Taylor R. Improvement in endothelial function by angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. J Am Coll Cardiol 1999;33:1506-11.
35. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993;21:929-33.
36. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in man - evidence for an aldosterone-induced vasculopathy. Clin Sci 2002;103:425-31.
37. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000;101:594-7.
38. Ascherio A, Rimm EB, Hernan MA et al. Intake of potassium, magnesium, calcium, and fiber and risk of stroke among US men. Circulation 1998;98:1198-204.
39. Feng J He, Graham A MacGregor. Fortnightly review: Beneficial effects of potassium. BMJ 2001;323:497-501.
40. Landin K, Lindgarde F, Saltin B, Wilhelmsen L. Increased skeletal muscle Na/K-ratio in obese men, but not in women, with glucose intolerance. J Intern Med 1989;225:89-94.
41. Guerrero-Romero F, Rodriguez-Moran M. Hypomagnesemia is linked to low serum HDL-cholesterol irrespective of serum glucose values. J Diabetes Complications 2000;14:272-6.
42. Lima M, Cruz T, Pousada JC, Rodrigues LE, Barbosa K, Cangucu V. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care 1998;21:682-6.
43. Bashir Y, Sneddon JF, Staunton HA et al. Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1993;72:1156-62.
44. Zehender M, Meinertz T, Faber T et al. Antiarrhythmic effects of increasing the daily intake of magnesium and potassium in patients with frequent ventricular arrhythmias. Magnesium in Cardiac Arrhythmias (MAGICA) Investigators. J Am Coll Cardiol 1997;29:1028-34.
45. Schmidt BM, Montealegre A, Janson CP et al. Short term cardiovascular effects of aldosterone in healthy male volunteers. J Clin Endocrinol Metab 1999;84:3528-33.
46. Shechter M, Sharir M, Labrador MJ, Forrester J, Silver B, Bairey Metz CN. Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 2000;102:2353-8.
47. Taddei S, Mattei P, Virdis A, Sudano I, Ghiadoni L, Salvetti A. Effect of potassium on vasodilation to acetylcholine in essential hypertension. Hypertension 1994;23:485-90.
48. Rossing K, Christensen PK, Jensen BR, Parving HH. Dual blockade of the renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002;25:95-100.
49. Takahashi N, Nakagawa M, Saikawa T et al. Effect of essential hypertension on cardiac autonomic function in type 2 diabetic patients. J Am Coll Cardiol 2001;38:232-7.
50. Liao D, Sloan RP, Cascio WE et al. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care 1998;21:2116-22.
51. Tsuji H, Larson MG, Venditti FJ Jr et al. Impact of reduced heart rate variability on risk for cardiac events. The Framingham Heart Study. Circulation 1996;94:2850-5.
52. Reaven GM, Lithell H, Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996;334:374-81.
53. Yee KM, Struthers AD. Aldosterone blunts the baroreflex response in man. Clin Sci 1998;95:687-92.
54. Barr CS, Naas A, Freeman M, Lang CC, Struthers AD. QT dispersion and sudden unexpected death in chronic heart failure. Lancet 1994;343:327-9.
55. MacFadyen RJ, Barr CS, Struthers AD. Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res 1997;35:30-4.
56. Malik RA. Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors? Ann Med 2000; 32:1-5.
57. Kontopoulos AG, Athyros VG, Didangelos TP et al. Effect of chronic quinapril administration on heart rate variability in patients with diabetic autonomic neuropathy. Diabetes Care 1997;20:355-61.
58. Nielsen FS, Ali S, Rossing P et al. Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy. Diabet Med 1997;14:538-46.
59. van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990;82:848-55.
60. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561-6.
61. Fujimoto WY, Williams RH. Insulin action on the cultured human fibroblast. Glucose uptake, protein synthesis, RNA synthesis. Diabetes 1974;23:443-8.
62. Rabkin SW, Dawson KG, Bhaumick B, O'Brein E, Kendler DL. Serum insulin, IGF-I, IGF-II and growth hormone, and left ventricular mass in non-insulin-dependent mellitus. Can J Cardiol 1996;12:264-70.
63. Brilla CG, Rupp H, Funck R, Maisch B. The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Eur Heart J 1995;16(suppl O):107-09.
64. Schlaich MP, Schobel HP, Hilgers K, Schmieder RE. Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol 2000;85:1199-206.
65. Tsutamoto T, Wada A, Maeda K et al. Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 2001;37:1228-33.
66. Ewing DJ, Boland O, Neilson JM, Cho CG, Clarke BF. Autonomic neuropathy, QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 1991;34:182-5.
67. Veglio M, Chinaglia A, Cavallo PP. The clinical utility of QT interval assessment in diabetes. Diabetes Nutr Metab 2000;13:356-65.